These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38291616)

  • 1. A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Damier P; Degos B; Castelonovo G; Anheim M; Benatru I; Carrière N; Colin O; Defebvre L; Deverdal M; Eusebio A; Ferrier V; Giordana C; Houeto JL; Le Dily S; Mongin M; Thiriez C; Tranchant C; Ravel D; Corvol JC; Rascol O; Ben Ari Y
    Mov Disord; 2024 Mar; 39(3):618-622. PubMed ID: 38291616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.
    Takeda A; Takahashi R; Tsuboi Y; Nomoto M; Maeda T; Nishimura A; Yoshida K; Hattori N
    Mov Disord; 2021 Feb; 36(2):415-423. PubMed ID: 33073879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.
    Rascol O; Medori R; Baayen C; Such P; Meulien D;
    Mov Disord; 2022 May; 37(5):1088-1093. PubMed ID: 35218231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opicapone versus placebo in the treatment of Parkinson's disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
    Chaudhuri KR; Odin P; Ferreira JJ; Antonini A; Rascol O; Kurtis MM; Storch A; Bannister K; Soares-da-Silva P; Costa R; Magalhães D; Rocha JF
    BMC Neurol; 2022 Mar; 22(1):88. PubMed ID: 35279112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
    Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
    Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
    Damier P; Hammond C; Ben-Ari Y
    Clin Neuropharmacol; 2016; 39(1):57-9. PubMed ID: 26757306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
    Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
    Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J
    Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.